KRSouth Korea
Efinopegdutide MASH data lift Hanmi valuations as MSD weighs Phase 3
Korean brokers have nearly doubled their value for Hanmi's licensed liver drug after MSD's Phase 2b MASH results. The comparison with Wegovy behind the move is indirect, and MSD has not decided on Phase 3.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itKorean brokers raised their value for Hanmi's licensed liver drug efinopegdutide after MSD's Phase 2b MASH results, with Hana nearly doubling its estimate to 513.3 billion won.
Korean brokers have raised their value for Hanmi Pharmaceutical's licensed liver drug after efinopegdutide MASH results from MSD's Phase 2b trial beat expectations, MoneyToday reported on 17 November. The weekly GLP-1 and glucagon dual agonist, which Hanmi licensed to MSD, cleared liver inflammation in most patients at the middle dose after 52 weeks. MSD has not yet decided whether to start Phase 3, and analysts expect that call in the first half of 2027. The comparison with Wegovy behind the excitement is indirect.
What the Phase 2b trial showed
Merck, known as MSD outside the United States and Canada, presented the 52 week results at The Liver Meeting in Denver on 9 November, with simultaneous publication in The Lancet, according to BioPharm International. The efinopegdutide MASH trial enrolled 386 adults with biopsy confirmed disease and moderate to advanced fibrosis, stages F2 and F3, and 381 received at least one dose. They were assigned to three efinopegdutide dose levels, placebo or an open label semaglutide reference arm. MASH resolution without worsening fibrosis, the primary measure, was reached by 56%, 63% and 61% of the low, middle and high dose groups, against 13% on placebo.
Fibrosis improved by at least one stage without MASH worsening in 43%, 52% and 34% of the three dose groups, compared with 21% on placebo, the trade journal reported, with no statistical testing reported for that measure. The weaker fibrosis result at the highest dose was not explained. Nausea and vomiting were the main side effects, and stopping treatment because of adverse events reached 3%, 4% and 11% across the dose groups, against 1% for both placebo and semaglutide. Hanmi first developed the molecule and licensed it to MSD, which now leads development, so Korean investors read every result as news about the future value of that deal for Hanmi.
Why Korean analysts compare it with Wegovy
The excitement in Seoul rests on an indirect comparison. At the middle dose, the placebo corrected gain was 49.5 percentage points for MASH resolution and 30.4 points for fibrosis improvement, MoneyToday reported. In Novo Nordisk's Phase 3 trial of Wegovy in MASH, which ran for 72 weeks, the corresponding gains were 28.7 and 14.4 points. For resmetirom, sold as Rezdiffra, the Phase 3 figures at 52 weeks were 20.2 and 11.7 points. On those numbers efinopegdutide looks stronger on both measures, and the article said this suggests possible superiority on key metrics. It also said comparisons between separate trials have clear limits of interpretation.
At the middle dose, the placebo corrected gain was 49.5 percentage points for MASH resolution and 30.4 points for fibrosis improvement, MoneyToday reported.
Those limits are real. The trials enrolled different patients, ran for different lengths of time and were run by different sponsors, and the semaglutide arm inside the efinopegdutide study was open label and not set up for a formal head to head test. Wi Jae-hoo of Korea Investment and Securities said the Phase 2b results were better than expected and also better than those of Wegovy, adding that earlier concerns about MSD handing the drug back had eased. Lee Ji-soo of Daol Investment and Securities pointed to two variables: Phase 2a results in patients with cirrhosis, stage F4, due in 2027, and whether MSD moves into Phase 3 at all.
Efinopegdutide MASH value in won
Brokers moved quickly to reprice the asset. Hana Securities raised its value for efinopegdutide from 278.8 billion won to 513.3 billion won and said further increases are possible if Phase 3 begins, according to MoneyToday. NH Investment and Securities put the drug at 524 billion won and lifted its estimated chance of entering Phase 3 from 20% to 28%, which it called a conservative assumption. NH also said Hanmi's total new drug pipeline could be valued above 6 trillion won next year, up from 4.551 trillion won now, depending on licensing deals and data. These are broker estimates, not company guidance, and they rest on decisions that MSD alone controls.
For Hanmi the licence structure is the key point. MSD leads development, so Hanmi's return depends on MSD's choices on Phase 3, dose and filing strategy. Hanmi said MSD is reviewing the programme and that it will share further plans, including Phase 3, at an appropriate time. That leaves the Korean company exposed to a portfolio decision taken outside Korea. Hanmi has other liver and metabolic assets, including the triple agonist efocipegtrutide, which recently gained a US use patent in lung damage and is in Phase 2 for MASH. Efinopegdutide is further along in the liver disease, which is why its data moved the broker models this week.
| Item | Detail |
|---|---|
| Drug | Efinopegdutide, MK-6024, GLP-1 and glucagon dual agonist |
| Origin | Hanmi Pharmaceutical, licensed to MSD |
| Trial | Phase 2b, 52 weeks, F2 and F3 fibrosis |
| Patients dosed | 381 |
| MASH resolution, middle dose | 63% against 13% on placebo |
| Fibrosis improvement, middle dose | 52% against 21% on placebo |
| Hana Securities value | 278.8 billion won raised to 513.3 billion won |
| NH Investment value | 524 billion won, Phase 3 odds raised from 20% to 28% |
| Phase 3 decision | Expected by brokers in the first half of 2027 |
What to watch next
The main marker is MSD's Phase 3 decision, which Korean brokers expect in the first half of 2027. Hana Securities has said a start would open room for further upgrades, while a delay would leave the new estimates resting on Phase 2 data alone. The second marker is the cirrhosis data due in 2027, because patients with stage F4 disease face the highest risk and have the fewest options. The third is tolerability. The higher dropout rate at the top dose suggests a narrower working range, and the Phase 3 design will show which dose MSD backs. Regulators usually also expect outcome data, not only biopsy results, before full approval in MASH.
For readers of the Asia Pacific desk, the result adds to a pattern of Korean companies building value through licensed metabolic peptides as well as through home launches. Hanmi already sells its own GLP-1 pen in Korea, and a KoreaBIO count reported this month listed six Korean obesity drug candidates among 30 discovered in the region, as we noted in our look at the Asia Pacific obesity pipeline. The efinopegdutide MASH data now give Hanmi's investors a concrete number to watch. Whether that number turns into a Phase 3 programme remains MSD's decision, and the timing has not been made public.
Conclusion
Efinopegdutide MASH results from MSD's Phase 2b trial cleared liver inflammation in most patients at the middle dose, and Korean brokers have nearly doubled their value for Hanmi's licensed drug. The comparison with Wegovy is indirect. MSD's Phase 3 decision, expected in the first half of 2027, and cirrhosis data the same year will decide whether the new valuations hold.
Why it matters in South Korea
Hanmi developed efinopegdutide and licensed it to MSD, so Korean investors price Hanmi on MSD's data and decisions. Strong but indirect comparisons with Wegovy have lifted broker estimates for the company's pipeline.
What to watch
MSD's Phase 3 decision, expected by brokers in the first half of 2027, and Phase 2a results in patients with F4 cirrhosis due in 2027.
Sources
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.